Detecting Ultra-Low Frequency ESR1 Mutations in Liquid Biopsy Samples Using the oncoReveal Essential LBx Panel
The oncoReveal® Essential LBx Panel is a single-tube, 34-gene amplicon-based NGS liquid biopsy assay built on SLIMamp® chemistry. Pillar tested it on Seraseq® ctDNA ESR1 reference standards diluted to 0.05% variant allele frequency (VAF) from 5–30 ng of plasma cell-free DNA (cfDNA), sequenced on the Illumina NextSeq 550 and analyzed with PiVAT® software. It detected these endocrine-therapy-resistance mutations in HR-positive breast cancer with 98.4% PPA at 0.1% VAF and 100% NPA — no molecular barcodes (UMIs) required.
Pillar Biosciences Enables Rapid, Localized Tumor Profiling of Lymphoid Malignancies with Launch of New Kitted NGS Panel
NATICK, Mass. – November 11, 2025– (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories to perform rapid tumor profiling of lymphoid malignancies. The oncoReveal Lymphoid panel interrogates 84 genes of interest, including full coding […]